Polypeptide Biomarkers for Brain Damage Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biological markers for brain damage-related disorders, such as cerebrovascular and neurodegenerative diseases, are not effective due to late appearance, poor sensitivity and specificity, and limited understanding of their release mechanisms, making them unsuitable for routine diagnosis.
Innovation Solution
Identification and use of specific polypeptides in cerebrospinal fluid from deceased patients as biomarkers, which can be detected in more readily available body fluids like blood, serum, or urine, to diagnose and monitor brain damage-related disorders, including cerebrovascular and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biomarkers (creatine kinase-BB, lactate dehydrogenase, myelin basic protein, S100 protein, NSE, GFAP, tau) are used for diagnosis, then the diagnostic process can be performed, but the markers appear late after brain damage, have poor sensitivity and specificity, and provide delayed clinical assessment
Solution Approach 1:
The patent performs proteomics analysis on CSF from deceased patients as a preliminary step to identify potential biomarkers before applying them to living patients. This preliminary action on post-mortem samples allows discovery of markers that appear early after brain damage, which then can be used for timely diagnosis in clinical settings.
Solution Approach 2:
The patent uses cerebrospinal fluid from deceased patients as a model system to copy and study the protein release patterns that occur after brain damage. This copying approach allows identification of biomarkers without the time constraints of waiting for marker appearance in living patients, thereby discovering early-appending markers for clinical use.
2Measurement precision
If CSF samples are obtained for biomarker detection, then brain-specific markers can be measured, but the sampling process is difficult and invasive
Solution Approach 1:
The patent uses deceased patients' CSF as an intermediary model to identify biomarkers that can subsequently be detected in more accessible body fluids of living patients. This intermediary approach allows discovery of brain-specific markers through CSF analysis while the actual clinical application uses easier-to-obtain samples like blood or urine.
Solution Approach 2:
The patent segments the diagnostic process into two parts: (1) biomarker discovery phase using CSF from deceased patients, and (2) clinical diagnosis phase using biomarkers detected in accessible body fluids of living patients. This segmentation allows optimization of each phase independently, using CSF only where it provides unique value for marker identification.
3Productivity
If biomarkers are used for routine diagnosis, then clinical assessment can be performed, but the limited understanding of release mechanisms and poor sensitivity reduce their utility
Solution Approach 1:
The patent changes the parameter of sample timing by analyzing CSF from deceased patients, which captures the full spectrum of protein release patterns after brain damage. This parameter change allows identification of markers with optimal sensitivity and specificity that may be missed in living patients due to timing constraints.
Solution Approach 2:
The patent uses proteomics technology to provide comprehensive feedback on protein composition changes in CSF after brain damage. This detailed feedback information allows identification of multiple potential biomarkers with different temporal patterns, enabling selection of the most sensitive and specific markers for routine diagnosis.
Data Source
AI summary
A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.